BioMimetic Therapeutics to Present at Canaccord Adams Global Growth ConferenceFranklin, Tenn. – August 7, 2009 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Steven Hirsch, COO and executive vice president of orthopedics, will provide an update of corporate activities at the 29th Annual Canaccord Adams Global Growth Conference on Wednesday, August 12th at 2:30 p.m. Eastern Time. The presentation is being held in the London Room at the InterContinental Boston in Boston, Mass. A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/canaccord/bmti/ and on the Company’s website at www.investor.biomimetics.com. The webcast will be accessible for a period of at least 30 days. About BioMimetic TherapeuticsBioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of the rhPDGF-BB platform technology. Additionally, the Company has clinical trials ongoing with its product candidates Augment and Augment Injectablein multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's previously approved product and lead product candidates all combine recombinant protein therapeutics (rhPDGF-BB) with tissue specific scaffolds to actively stimulate tissue healing and regeneration. GEM 21S® is the registered trademark of Luitpold Pharmaceuticals, Inc., who now owns and markets that product. For further information, contact Kearstin Patterson, corporate communications, at 615-236-4419. |